Border seizures of personal drug imports: what the data shows

A patient considering personal importation wants concrete numbers: how likely is a package to be seized, what happens if it is, and what gets seized most often? This page gives the data that is publicly available — and is honest about the large gaps in it.

How often are personal-import packages seized?

There is no reliable numeric answer, and that itself is the most important fact. Government oversight has repeatedly found the data does not exist: the Government Accountability Office reported that neither CBP nor FDA systematically collects data on the volume of personal prescription-drug imports.[1] That finding has not been superseded — the most recent GAO review of CBP drug-seizure data, covering fiscal years 2016 through 2021, found CBP still had not assessed whether its drug-type categories adequately capture the scenarios its officers encounter, and it produced no personal-import prescription-drug seizure rate.[2]

What can be said is structural rather than statistical: CBP and FDA process enormous package volume; the FDA’s published manual directs inspectors to focus on commercial and high-risk shipments rather than individual patient orders; and the categories that dominate seizure records (controlled substances, commercial-pattern shipments, entities on FDA Import Alerts) are not the typical personal-import profile. The available data does not support a reliable estimate of the likelihood that any individual shipment will be intercepted.

What CBP and FDA actually intercept

The most detailed public data comes from a GAO investigation of CBP and FDA International Mail Facility operations in 2004–2005. By June 2004, CBP at one International Mail Branch had accumulated 123 bins of mail containing over 40,700 packages of Schedule IV controlled substances — including diazepam (Valium), antidepressants, and painkillers.[3] A follow-up covering September 2004 through June 2005 documented approximately 61,700 packages of Schedule III–V controlled substances interdicted — about 61,500 at international mail facilities and 200 at express carrier facilities.[4] Three observations follow.

Controlled substances dominate the recorded data. The GAO figures cover scheduled drugs specifically. Non-controlled prescription drug seizures occur but are not aggregated the same way, and the volume is much smaller — reflecting enforcement priorities, since controlled substances are treated as a public-safety matter and recorded, while non-controlled drugs are more often handled as routine matters and may be released, returned, or destroyed without formal seizure paperwork.

The drugs recorded are predictable. Diazepam, certain antidepressants, and scheduled painkillers — the profile of what is ordered from unregulated online sources and what draws CBP and DEA attention.

Many “interdictions” are abandonments, not formal seizures. GAO documented that CBP may hold Schedule III–V packages as unclaimed or abandoned property rather than seizing them, because abandonment requires far less paperwork — a CBP headquarters official described the abandonment process as taking an inspector about one minute per package.[4] If the addressee abandons the package or does not respond within the notice period, it becomes eligible for destruction. No criminal action follows.

What CBP’s current public data shows — and what it doesn’t

CBP publishes drug-seizure statistics on its public newsroom page, updated through each fiscal year. But that dashboard tracks illicit drugs — cocaine, methamphetamine, heroin, fentanyl, marijuana — not personal-import prescription seizures.[5] Prescription drugs imported for personal use are not separately reported in the public aggregate. There is no published annual figure for “prescription drugs seized from personal-import packages” the way there is for cocaine or fentanyl. The data that exists is partial and, for the detailed personal-import picture, two decades old.

What happens when a personal-import shipment is intercepted

For a non-controlled prescription drug, the typical sequence is:

1. Interception. CBP and FDA personnel screen packages at mail facilities, express carrier hubs, or land crossings; those appearing to contain unapproved drugs are set aside for FDA review.
2. FDA review. Personnel assess whether the shipment fits the manual’s enforcement-discretion criteria — personal use, reasonable quantity, no commercialization concern.[6]
3. Determination. The shipment may be released, refused, or detained pending more information.
4. Notice. If admission is refused, the FDA notifies the addressee with the reason and the available options.
5. Response. The addressee may provide documentation, abandon the shipment, or contest the refusal.
6. Outcome. Most addressees abandon; the shipment is destroyed; no criminal action follows; the event may flag future shipments to the same address.

For controlled substances the process differs sharply: a Schedule I or II substance may be summarily forfeited without notice, while for Schedule III–V substances CBP notifies the addressee and offers an opportunity to contest forfeiture.[4] See the companion page on controlled substances.

What CBP looks for

Federal agencies use risk-based screening and enforcement priorities when reviewing shipments. Publicly available materials discuss categories of concern, but those materials should not be understood as a guide for predicting, avoiding, or influencing inspection decisions: country of origin (sources associated with counterfeit supply chains draw scrutiny; CBP and FDA do not distinguish legitimate from illegitimate shippers in a given country at the border); quantity (shipments beyond a 90-day supply are more likely treated as commercial, and multiple shipments to one address can be aggregated); sender identification (entities on FDA Import Alerts are subject to automatic detention);[7] packaging (missing prescription documentation, manufacturer labeling, or country-of-origin marking invites inspection); and declared content (misdeclaring a pharmaceutical as something else can create additional legal exposure beyond the import issue).[8]

This site does not provide legal advice and cannot assess your specific situation. Consult a U.S.-licensed attorney for questions about your individual circumstances.